Hair Loss Treatment Options: Minoxidil, Finasteride, PRP, and Hair Transplants

The Treatment You Choose Matters More Than You Think — Half of Men Are Affected by 50

Androgenetic alopecia (AGA) — pattern hair loss — is the most common cause of hair loss worldwide, affecting approximately 50% of men by age 50 and 25–40% of women by age 70. In men, it follows the Norwood-Hamilton classification of frontal recession and crown thinning; in women, it typically presents as diffuse central crown thinning with preservation of the frontal hairline (Ludwig scale). The driving mechanism is the conversion of testosterone to dihydrotestosterone (DHT) by 5-alpha reductase enzymes in hair follicles, with DHT binding androgen receptors in genetically susceptible follicles and progressively miniaturizing them through shortened anagen (growth) phases and lengthened telogen (rest) phases.

Treatment works best when started early — waiting until significant visible thinning is obvious means millions of follicles have already been irreversibly miniaturized.

First-Line Treatments: Minoxidil and the 5-Alpha Reductase Inhibitors

Two treatments have been FDA-approved for AGA for decades and have the broadest evidence base: minoxidil and finasteride (in men).

Minoxidil was originally developed as an oral antihypertensive drug in the 1970s before hypertrichosis was noted as a side effect. Topical formulations (2% and 5%) became the first FDA-approved hair loss treatments. Minoxidil's mechanism in hair follicles is incompletely understood but involves potassium channel opening that prolongs the anagen phase and increases follicular blood flow. Key facts about minoxidil:

• 5% topical solution/foam outperforms 2% in both sexes; once-daily foam is as effective as twice-daily solution with better tolerability
• Oral low-dose minoxidil (0.25–5 mg/day) has gained significant evidence and clinical adoption since 2020, showing superior efficacy to topical in many comparative studies; particularly useful for patients with scalp sensitivity
• Requires continuous use — hair shed from stopped treatment within 3–6 months of discontinuation
• Initial "shedding phase" (telogen effluvium) in the first 4–8 weeks is expected and predictive of response
• Response rate: approximately 60% of users show stabilization or regrowth; peak effect at 12 months

Finasteride (Propecia, 1 mg/day) is a Type II 5-alpha reductase inhibitor that reduces serum DHT by approximately 70%. Multiple clinical trials demonstrated arrest of hair loss progression in 86% of men and visible regrowth in 65% at 2 years. It is FDA-approved only for men. Key considerations:

• Sexual side effects (decreased libido, erectile dysfunction, ejaculation disorders) occur in approximately 1.4–2% in controlled trials, though nocebo effects inflate real-world reporting; persistent post-finasteride syndrome (continuing sexual dysfunction after stopping) is rare but recognized
• Requires continuous use; stopping leads to hair loss resumption within 6–12 months
• Reduces PSA levels by approximately 50% — important context for prostate cancer screening interpretation

Platelet-Rich Plasma (PRP) Therapy

Platelet-rich plasma (PRP) therapy involves drawing a small amount of the patient's blood, centrifuging it to concentrate the platelet fraction (3–5× normal concentration), and injecting the resulting plasma into the scalp. Platelets release growth factors — PDGF, VEGF, TGF-beta, EGF, IGF-1 — that may stimulate follicular stem cells, prolong the anagen phase, and reduce follicular inflammation.

The evidence base for PRP has grown substantially since 2015. A 2019 meta-analysis of 19 studies found significant increases in hair density, follicular unit density, and hair caliber compared to controls, with average increases of approximately 30–40% in hair count in treated areas. However, study quality is variable, preparation protocols differ widely between providers (platelet concentration, activation method, injection technique), and standardization of optimal dosing frequency remains elusive. Most protocols involve 3–4 monthly sessions followed by maintenance treatments every 3–6 months.

Hair Transplant Surgery: FUT and FUE

Hair transplant surgery permanently relocates DHT-resistant follicles from the "donor-dominant" occipital and temporal scalp to areas of thinning. These relocated follicles retain their DHT resistance regardless of location — the basis of donor dominance theory and the permanence of transplant results. Two techniques dominate:

• Follicular unit transplantation (FUT / "strip" method): A strip of scalp is surgically excised from the donor area; follicular units are dissected under microscopy; strip site closed, leaving a linear scar; yields large numbers of grafts (2,000–3,000+) in a single session; scar concealment requires longer hair
• Follicular unit extraction (FUE): Individual follicular units are extracted directly from the donor area with a small punch device (0.8–1.0 mm); no linear scar (small round puncture scars); greater donor area trauma per graft; technique-sensitive; allows shorter haircuts post-procedure; robotic FUE systems (ARTAS) offer consistency but do not demonstrably outperform skilled manual FUE surgeons

Realistic expectations are essential: transplanted hair falls out 2–3 weeks post-procedure (shock loss), with new growth beginning at 3–4 months and full density appearing at 12–18 months. Medical therapy (minoxidil, finasteride) is typically continued post-transplant to protect non-transplanted native hair from ongoing miniaturization. Candidates must have adequate donor density and stable hair loss — transplanting into actively progressive AGA without medical therapy risks progressive "framing" effect as surrounding native hair continues to recede.

Emerging Treatments: JAK Inhibitors and Beyond

JAK inhibitors — originally developed for alopecia areata (an autoimmune hair loss condition distinct from AGA) — are approved for severe alopecia areata (baricitinib, ritlecitinib) and show dramatic results in that condition. Their role in androgenetic alopecia is under investigation. Stem cell-derived conditioned media, Wnt pathway activators, and prostaglandin D2 antagonists represent additional investigational avenues, with several compounds in phase 2 trials as of 2026.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.